Christopher John Kenney - Mar 12, 2025 Form 4 Insider Report for Xenon Pharmaceuticals Inc. (XENE)

Role
Chief Medical Officer
Signature
/s/ Nathaniel Adams, Attorney-in-fact
Stock symbol
XENE
Transactions as of
Mar 12, 2025
Transactions value $
$0
Form type
4
Date filed
3/13/2025, 07:31 PM
Previous filing
Mar 12, 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XENE Share Option (Right to Buy) Award $0 +80K $0.00 80K Mar 12, 2025 Common Shares 80K $35.48 Direct F1
transaction XENE Restricted Share Units Award $0 +15K $0.00 15K Mar 12, 2025 Common Shares 15K $0.00 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Vesting 25% on March 12, 2026, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.
F2 Each restricted share unit represents a contingent right to receive one Common Share vesting 25% on each of the first four anniversaries of the date of grant, beginning on March 12, 2026.